PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring health and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation.
PAQ uses its ATTEC (autophagosome-tethering compound) technology, where small molecules can selectively enhance the degradation of disease causing entities. PAQ’s research advances are driving an important new class of degradation therapies with the potential to target a range of substrates including proteins, aggregates, lipids, organelles and pathogens.
The company’s initial focus is on a genetic neurodegenerative disorder with no current treatment options for patients. PAQ plans to expand the ATTEC platform to target additional disease-causing protein and non-protein targets.
PAQ was founded in 2020 by Boxun Lu, Huaixiang Hao, and Nan Ji, and raised US $30 million is a Series A round in July 2021.
Subscribe for alerts on new companies featured on Startups.Bio
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections. BioTryp's …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and autoimmune diseases. Bastion's GRIT™ (Genetically …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new class of genomic medicines that …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for developing gene therapies for brain …